Literature DB >> 19142737

Occurrence of TRGV-BJ hybrid gene in SV40-transformed fibroblast cell lines.

L P G D'Arce1, C L Bassi, A L Fachin, G A S Passos, E T Sakamoto-Hojo.   

Abstract

Illegitimate V(D)J-recombination in lymphoid malignancies involves rearrangements in immunoglobulin or T-cell receptor genes, and these rearrangements may play a role in oncogenic events. High frequencies of TRGV-BJ hybrid gene (rearrangement between the TRB and TRG loci at 7q35 and 7p14-15, respectively) have been detected in lymphocytes from patients with ataxia telangiectasia (AT), and also in patients with lymphoid malignancies. Although the TRGV-BJ gene has been described only in T-lymphocytes, we previously detected the presence of TRGV-BJ hybrid gene in the genomic DNA extracted from SV40-transformed AT5BIVA fibroblasts from an AT patient. Aiming to determine whether the AT phenotype or the SV40 transformation could be responsible for the production of the hybrid gene by illegitimate V(D)J-recombination, DNA samples were extracted from primary and SV40-transformed (normal and AT) cell lines, following Nested-PCR with TRGV- and TRBJ-specific primers. The hybrid gene was only detected in SV40-transformed fibroblasts (AT-5BIVA and MRC-5). Sequence alignment of the cloned PCR products using the BLAST program confirmed that the fragments corresponded to the TRGV-BJ hybrid gene. The present results indicate that the rearrangement can be produced in nonlymphoid cells, probably as a consequence of the genomic instability caused by the SV40-transformation, and independently of ATM gene mutation.

Entities:  

Mesh:

Year:  2009        PMID: 19142737     DOI: 10.1007/s10709-008-9348-5

Source DB:  PubMed          Journal:  Genetica        ISSN: 0016-6707            Impact factor:   1.082


  50 in total

Review 1.  Viruses and the cell cycle.

Authors:  A Op De Beeck; P Caillet-Fauquet
Journal:  Prog Cell Cycle Res       Date:  1997

2.  Identification of the complete expressed human TCR V gamma repertoire by flow cytometry.

Authors:  T Hinz; D Wesch; F Halary; S Marx; A Choudhary; B Arden; O Janssen; M Bonneville; D Kabelitz
Journal:  Int Immunol       Date:  1997-08       Impact factor: 4.823

3.  Disregulation of mitotic checkpoints and regulatory proteins following acute expression of SV40 large T antigen in diploid human cells.

Authors:  T H Chang; F A Ray; D A Thompson; R Schlegel
Journal:  Oncogene       Date:  1997-05-22       Impact factor: 9.867

4.  Presence of simian virus 40 sequences in malignant mesotheliomas and mesothelial cell proliferations.

Authors:  N Shivapurkar; T Wiethege; I I Wistuba; E Salomon; S Milchgrub; K M Muller; A Churg; H Pass; A F Gazdar
Journal:  J Cell Biochem       Date:  1999-12       Impact factor: 4.429

5.  The influence of SV40 immortalization of human fibroblasts on p53-dependent radiation responses.

Authors:  M Kohli; T J Jorgensen
Journal:  Biochem Biophys Res Commun       Date:  1999-04-02       Impact factor: 3.575

Review 6.  Ataxia telangiectasia gene mutations in leukaemia and lymphoma.

Authors:  J Boultwood
Journal:  J Clin Pathol       Date:  2001-07       Impact factor: 3.411

Review 7.  Responses to DNA damage and regulation of cell cycle checkpoints by the ATM protein kinase family.

Authors:  M F Hoekstra
Journal:  Curr Opin Genet Dev       Date:  1997-04       Impact factor: 5.578

8.  Kinds and locations of mutations induced in the hypoxanthine-guanine phosphoribosyltransferase gene of human T-lymphocytes by 1-nitrosopyrene, including those caused by V(D)J recombinase.

Authors:  W G McGregor; V M Maher; J J McCormick
Journal:  Cancer Res       Date:  1994-08-01       Impact factor: 12.701

Review 9.  Simian virus 40, poliovaccines and human tumors: a review of recent developments.

Authors:  M Carbone; P Rizzo; H I Pass
Journal:  Oncogene       Date:  1997-10-16       Impact factor: 9.867

Review 10.  Cell and molecular biology of simian virus 40: implications for human infections and disease.

Authors:  J S Butel; J A Lednicky
Journal:  J Natl Cancer Inst       Date:  1999-01-20       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.